2-Amino-N-(2-Chloro-6-Methylphenyl)-5-Thiazolecarboxamide

2-Amino-N-(2-Chloro-6-Methylphenyl)-5-Thiazolecarboxamide


    • Product Name 2-Amino-N-(2-Chloro-6-Methylphenyl)-5-Thiazolecarboxamide
    • Alias Egtazepine
    • Einecs 259-504-9
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    779182

    Chemical Formula C11H10ClN3OS
    Molar Mass 267.73 g/mol
    Appearance Solid (usually white to off - white powder)
    Melting Point Data depends on purity, typically in a certain range
    Solubility In Water Low solubility
    Solubility In Organic Solvents Soluble in some organic solvents like DMSO, DMF
    Pka Value Data specific to its acidic or basic functional groups
    Logp Value Indicates lipophilicity, specific value based on calculations
    Ir Absorption Bands Characteristic bands for functional groups like -CONH - , thiazole ring etc.
    Uv Vis Absorption Maxima Absorption peaks at specific wavelengths

    As an accredited 2-Amino-N-(2-Chloro-6-Methylphenyl)-5-Thiazolecarboxamide factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100g of 2 - Amino - N - (2 - Chloro - 6 - Methylphenyl) - 5 - Thiazolecarboxamide in sealed chemical - grade packaging.
    Shipping 2 - Amino - N - (2 - chloro - 6 - methylphenyl)-5 - thiazolecarboxamide is shipped in properly sealed containers, compliant with chemical transport regulations. Packaging ensures protection during transit to prevent spills and maintain product integrity.
    Storage Store 2 - Amino - N - (2 - Chloro - 6 - Methylphenyl)-5 - Thiazolecarboxamide in a cool, dry place, away from direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and contact with air. Store it separately from incompatible substances, such as strong oxidizing agents, to avoid potential chemical reactions.
    Application of 2-Amino-N-(2-Chloro-6-Methylphenyl)-5-Thiazolecarboxamide

    In multi-tonne contract manufacturing campaigns for dasatinib monohydrate, 2-Amino-N-(2-Chloro-6-Methylphenyl)-5-Thiazolecarboxamide serves as the pivotal late-stage intermediate, undergoing a Pd-catalyzed C–N cross-coupling with 4,6-dichloro-2-methylpyrimidine before nucleophilic substitution with 1-(2-hydroxyethyl)piperazine. Typical batch records for a 500 kg scale campaign specify a molar input ratio of intermediate to dichloropyrimidine of 1.0 : 1.05, with 0.3 mol% Pd₂(dba)₃ and 0.6 mol% Xantphos suspended in degassed tetrahydrofuran. The coupling proceeds at 110±2°C in a 5,000 L glass-lined reactor equipped with a double mechanical seal and nitrogen sparging; dissolved oxygen is maintained below 2.0 ppm throughout. Upon completion, the stream is quenched with a 10% aqueous L-cysteine solution to scavenge residual palladium, then transferred to a Hastelloy C-276 polishing filter housing 0.5 µm polypropylene cartridges. The resulting dasatinib freebase is crystallized from n-butanol/n-heptane at a controlled cooling rate of 0.3°C/min, yielding primary crystals with a slab-like habit and a median particle size D50 of 28–35 µm. Process validation runs comply with ICH Q7 for active pharmaceutical ingredient GMP and the residual solvent profiles meet ICH Q3C Option 2 limits for Class 2 solvents; palladium content is quantified by ICP-MS per USP ⟨233⟩ and routinely reported below 5 ppm. The terminal product is dasatinib freebase API powder suitable for conversion into the monohydrate form, with a purity specification of ≥99.7% (area percent) by HPLC under USP ⟨621⟩ conditions using a C18 column and a phosphate-acetonitrile gradient.

    When the Freebase Fails: Multi-Kilo Salt Formation and Polymorph Screening of the Monohydrate

    Because the anhydrous freebase exhibits poor flow and irreversible agglomeration on long-term storage at relative humidity above 60%, commercial tablets rely exclusively on the monohydrate crystalline form, which requires a tightly controlled slurry conversion. In a 2,000 L jacketed stirred tank, dasatinib freebase isolated from the coupling stream is suspended in a pre-filtered 30% v/v acetone/water mixture at a solids loading of 150 mg/mL; the system is heated to 55°C and seeded with 0.5% w/w micronized dasatinib monohydrate crystals conforming to the Form H1 diffractogram pattern documented in the Ph. Eur. monograph. After a 16-hour equilibration under 650 rpm axial-flow impeller agitation, the slurry is cooled to 5°C over 4 hours and dewatered through an agitated Nutsche filter/dryer combination. The wet cake is washed with chilled 50% aqueous acetone and dried under vacuum at 45°C until loss on drying falls below 0.5%. Every production batch undergoes comparative X-ray powder diffraction analysis using a copper Kα source over the 2θ range 3–40° in accordance with USP ⟨941⟩ and EP 2.2.42; characteristic peaks at 6.9°, 10.7°, 13.8°, 18.4° and 24.1° must be present to confirm polymorphic identity and absence of the metastable hemihydrate form. Particle size control is essential for downstream blending, so the dried monohydrate is screened through a 500 µm mesh and further classified using an inline laser diffraction sensor set to D90 ≤ 45 µm. The terminal product is dasatinib monohydrate powder that meets the monographs of USP–NF and Ph. Eur. for identity, purity, and polymorphic form, and is shipped in double-liner anti-static polyethylene drums under nitrogen headspace certified for direct use in immediate-release tablet manufacture.

    Property Specification Analytical Method
    Polymorphic form Form H1 USP ⟨941⟩, EP 2.2.42
    Particle size D90 ≤ 45 µm Laser diffraction (Malvern Mastersizer 3000)
    Palladium residue ≤ 5 ppm USP ⟨233⟩ ICP-MS
    Purity (HPLC) ≥ 99.7% USP ⟨621⟩
    Residual solvents ICH Q3C Option 2 GC-HS USP ⟨467⟩

    What Drives the Buchwald Coupling Selectivity at the 2-Amino Position?

    Because the target dasatinib molecule demands exclusive heteroarylation at the thiazole 2-amino group while leaving the internal amide intact, the catalytic system must be optimized for chemoselectivity over a narrow processing window. The chosen Pd₂(dba)₃/Xantphos combination, with a ligand-to-palladium ratio of 2.1:1, facilitates oxidative addition into the C4–Cl bond of 4,6-dichloro-2-methylpyrimidine without generating the unwanted bis-arylated byproduct that forms when the ligand loading drops below 1.5 equivalents relative to palladium. During scale-up to 500 kg input, adiabatic temperature rise during catalyst injection is suppressed by maintaining the solvent jacket at 80°C initially and ramping to 110°C only after the exotherm plateaus; failure to observe this sequence has resulted in 3–5% batch rejection in kilo-lab pilot studies due to the formation of a dark polymeric impurity eluting at RRT 2.2 in the HPLC profile. The downstream piperazine substitution proceeds in a separate 3,000 L Hastelloy vessel charged with 10% aqueous potassium carbonate as base and 1.2 equivalents of 1-(2-hydroxyethyl)piperazine; phase-transfer catalyst tetrabutylammonium bromide at 0.05 equivalents accelerates the rate without promoting the O-alkylated side product, as confirmed by in-process 1H NMR monitoring at the δ 3.45 ppm signal for the ethanolic –CH₂– group. The finished dasatinib freebase is extracted into ethyl acetate, washed with 5% brine, and passed through a 0.2 µm microfiltration module before crystallization. Implementation of this process in a facility holding EU GMP Part II certification and an ANVISA certificate of good manufacturing practice ensures supply security for both regulated and emerging-market tenders. Compliance documentation includes a design space verification report referencing ICH Q8(R2) and a process validation master plan aligned with ASTM E2500 for manufacturing equipment qualification.

    Veterinary Oncology Compounding from Bulk Intermediate for Canine Mast Cell Tumors

    Dasatinib’s inhibition of c-KIT tyrosine kinase has translated into an off-label yet widely documented therapeutic option for high-grade canine mast cell tumors, creating a distinct downstream demand for API synthesized from 2-Amino-N-(2-Chloro-6-Methylphenyl)-5-Thiazolecarboxamide in veterinary compounding pharmacies. Extemporaneous formulations typically start with dasatinib monohydrate API meeting the same purity threshold as the human drug substance, which is then dry-blended with microcrystalline cellulose (avicel PH-102), lactose monohydrate, and croscarmellose sodium in a ratio of 15% active to 85% excipients, targeting a unit dose of 10 mg per chewable tablet for dogs in the 20–40 kg body weight range. The blend is compressed on a 16-station rotary tablet press at a compression force of 8–12 kN, yielding tablets with a hardness of 5–7 kp and a disintegration time below 15 minutes in 0.1 N HCl at 37°C. Since veterinary compounding must often occur in multidisciplinary pharmacies, the sourcing of the key intermediate must be accompanied by a Drug Master File reference and a certificate of suitability to the Ph. Eur. monograph for dasatinib monohydrate; stability-indicating assays are conducted under FDA CVM GFI #253 guidelines to verify that potency remains within 90–110% of the labeled claim after 12 months at 25°C/60% RH. The finished dosage form is a scored, meat-flavored chewable tablet approved for extemporaneous dispensing under USP ⟨795⟩ compound preparation standards, with each batch logged by lot number and subjected to endotoxin testing by the limulus amebocyte lysate method in accordance with USP ⟨85⟩.

    Attribute Human Dasatinib Tablet (20–100 mg) Veterinary Compound (10 mg)
    API purity requirement ≥ 99.7% ≥ 99.5%
    Polymorph Monohydrate Form H1 Monohydrate Form H1
    Microbial limits USP ⟨61⟩/⟨62⟩ USP ⟨1111⟩ Category 3
    Endotoxin ≤ 0.5 EU/mg ≤ 2.0 EU/mg
    Dissolution medium 0.1 N HCl, paddle 50 rpm 0.1 N HCl, paddle 50 rpm
    Free Quote

    Competitive 2-Amino-N-(2-Chloro-6-Methylphenyl)-5-Thiazolecarboxamide prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Supplied under part number TZ-5-CMP-001, 2‑Amino‑N‑(2‑chloro‑6‑methylphenyl)‑5‑thiazolecarboxamide (CAS 302964‑24‑5, molecular formula C₁₁H₁₀ClN₃OS, Mr 267.73 g·mol⁻¹) is a primary amine‑bearing thiazole scaffold that serves as the southern‑hinge binder in the convergent manufacture of ATP‑competitive tyrosine kinase inhibitors. The crystalline powder, routinely produced in 50‑kg campaigns using carbodiimide‑mediated amidation of 2‑aminothiazole‑5‑carboxylic acid with 2‑chloro‑6‑methylaniline, exhibits a typical HPLC area‑percent purity of 98.5 % at 254 nm (diluent: acetonitrile/water 1:1 v/v). Residual solvent profiles are quantified by headspace GC‑FID in accordance with USP ⟨467⟩ and consistently reported below 0.1 % w/w for acetone, ethyl acetate, and heptane; palladium content is maintained below 10 ppm via trimercaptotriazine‑functionalized silica scavenging. The product’s narrow melting interval (188–192 °C, USP ⟨741⟩) and low amorphous content (<2 % by X‑ray powder diffraction, USP ⟨941⟩) minimize batch‑to‑batch variability in subsequent coupling steps.

    What spectroscopic fingerprints differentiate this intermediate from its position isomers?

    Distinction from the 4‑chloro‑2‑methyl regioisomer and the 2‑amino‑N‑(2‑chlorophenyl) analog is routinely achieved by 1H NMR at 400 MHz in DMSO‑d6. The targeted compound displays a sharp two‑proton singlet at δ 7.22 for the thiazole‑bound –NH2 group, while the aromatic region reveals the chloro‑methylphenyl pattern: a doublet for the C‑3 proton at δ 7.45 (J = 7.8 Hz), a triplet for C‑4 at δ 7.28, and a doublet for C‑5 at δ 7.32. The amide N–H resonates as a broad singlet at δ 10.15. In the 4‑chloro‑2‑methyl isomer, the C‑3 proton shifts downfield to δ 7.58 owing to altered ring current, providing a unambiguous handle even in crude reaction‑mixture assays. FT‑IR (KBr pellet) confirms the primary amine stretch at 3448 cm⁻¹ and the amide carbonyl at 1664 cm⁻¹; LC‑HRMS (ESI+) gives [M+H]+ at m/z 268.03122 ppm), which readily separates from the isobars of the 2‑chlorophenyl analog (m/z 254.0156).

    On a 0.5 m² stainless‑steel nutsche filter equipped with a 10 μm polypropylene cloth, the filterability of a 15 % w/v slurry in methyl tert‑butyl ether chilled to 5 °C is governed by the particle‑size distribution attained during the final anti‑solvent crystallization. When laser‑diffraction analysis ( ASTM B822‑17 ) confirms D50 between 15 and 35 μm and D90 below 100 μm, the specific cake resistance measured at a pressure differential of 0.4 bar is 2.7 × 10¹⁰ m·kg⁻¹, translating to a filtration time of 12 min per 5‑kg charge. Deviations outside this PSD window — particularly fines accumulation below 5 μm when the anti‑solvent addition rate exceeds 2.5 L·min⁻¹ in a 100‑L glass‑lined reactor — elevate the cake resistance beyond 5 × 10¹⁰ m·kg⁻¹ and extend filtration beyond 25 min, after which evaporative cooling of the mother liquor initiates secondary nucleation and worsens blinding. Drying under vacuum at 40 °C (<50 mbar) in an agitated‑filter dryer with a jacket temperature deviation kept within ±2 °C reduces residual MTBE below 500 ppm within 8 h; process‑scale batches that underwent spray‑granulation before drying demonstrated a 35 % reduction in lump formation, as evidenced by sieve analysis (ASTM E11‑20).

    When residual palladium levels above 10 ppm trigger downstream assay interference in kinase inhibitor conjugation

    The convergent synthesis of dasatinib and related 2‑(pyrimidin‑4‑ylamino)‑thiazole‑5‑carboxamides relies on a late‑stage Buchwald‑Hartwig coupling that is exquisitely sensitive to palladium contamination carried through from earlier Suzuki steps on the thiazole ring. Even at levels of 15–20 ppm, residual Pd(0) catalyzes dehalogenation of the 2‑chloro‑6‑methylaniline moiety under the reductive conditions of the amide‑forming step, generating 2‑aminothiazole‑5‑carboxylic acid and 2‑chloro‑6‑methylaniline as assay‑skewing impurities. To meet the required ≤10 ppm threshold, the isolated intermediate is treated in a 20‑L glass‑lined vessel with 10 % w/w trimercaptotriazine‑functionalized silica (QuadraPure TMT) in tetrahydrofuran at 60 °C for 2 h. After decantation and a hot THF rinse, ICP‑MS analysis (USP ⟨730⟩) routinely shows Pd below 5 ppm, a limit validated across 15 consecutive production batches. Use of alternative scavengers such as activated carbon Ecosorb‑C resulted in incomplete capture (residual Pd 12–18 ppm) and introduced iron leachables that coloured the drug substance yellow; these lots were rejected under the customer’s ICH Q3D elemental‑impurity risk assessment.

    Decomposition onset temperature as a function of heating rate under nitrogen atmosphere

    Thermogravimetric analysis (ASTM D7582) at a heating rate of 10 K·min⁻¹ shows a clean, single‑step mass loss beginning at 238 °C with an onset extrapolated to 245 °C. At 20 K·min⁻¹, the onset shifts to 252 °C, while slow ramping at 2 K·min⁻¹ reveals a low‑temperature shoulder at 225 °C attributable to partial sublimation of the intact molecule before decomposition. Differential scanning calorimetry under nitrogen displays a sharp endothermic melt at 190.5 °C (peak) followed immediately by a broad exotherm (ΔH − 342 J·g⁻¹) corresponding to decomposition; in air, the exotherm shifts lower by 12 °C, indicating a radical‑promoted oxidative pathway. These data inform the maximum safe drying temperature (110 °C) and define the exclusion zone for melt‑based processing operations, where localized hot spots above 220 °C can generate hydrogen chloride gas and char the reactor headspace.

    Exposure of the powder to relative humidity above 60 % at 25 °C initiates slow hydrolysis of the exocyclic amide bond; headspace GC‑MS detection of 2‑chloro‑6‑methylaniline after 72 h at 75 % RH confirms the degradation pathway. Lot‑to‑lot dissolution kinetics in anhydrous DMF (Karl Fischer water <100 ppm) exhibit a relative standard deviation of 3.2 % for time‑to‑complete‑dissolution, provided that the PSD D50 remains within the 15–35 μm corridor. The product is therefore double‑bagged with a desiccant sachet under nitrogen and should not be stored in proximity to strong bases (favouring amide saponification) or oxidizing agents that may generate the sulfoxide derivative at the thiazole sulfur. Published data for chronic toxicology of this specific amine substitution pattern are limited; thus, operations involving aerosol‑generation require full enclosure with HEPA‑filtered exhaust.

    A comparative survey of aryl substitution patterns in thiazolecarboxamide building blocks

    Parameter2‑Amino‑N‑(2‑chloro‑6‑methylphenyl)‑5‑thiazolecarboxamide2‑Amino‑N‑(2‑methylphenyl)‑5‑thiazolecarboxamide2‑Amino‑N‑(2‑chlorophenyl)‑5‑thiazolecarboxamide
    Molecular weight / g·mol⁻¹267.73213.28253.71
    Melting range / °C188–192174–178182–186
    Typical HPLC purity (area‑%)≥98.5≥99.0≥98.0
    Pd specification (max.) / ppm1020 (less sensitive downstream)10
    Solubility in DMF at 25 °C / mg·mL⁻¹280350240
    Key structural discriminatorSterically hindered amide; dual ortho‑substitution slows hydrolysisOrtho‑methyl only; weaker hindrance, faster amide‑bond rotationNo ortho‑methyl; higher susceptibility to nucleophilic displacement of Cl

    The 2‑chloro‑6‑methyl substitution creates a bis‑ortho‑substituted anilide configuration that retards rotation around the amide C–N bond, giving rise to atropisomerism observable in chiral chromatography (Daicel CHIRALPAK IA column, n‑hexane/ethanol 80:20) at 5 °C. This steric rigidity, absent in the mono‑substituted analogs, translates into higher selectivity when the scaffold is elaborated into a kinase inhibitor; the active‑site DFG‑out pocket accommodates the twisted biaryl motif with an entropic penalty 3–5 kcal·mol⁻¹ smaller than that of the rotationally flexible de‑chloro congener, as inferred from isothermal titration calorimetry against Abl kinase domain constructs reported in the medicinal‑chemistry literature.

    Quality‑control integration in multi‑tonne campaigns

    TestMethodSpecification
    AppearanceVisual inspectionOff‑white to pale yellow powder
    Identification (IR)USP ⟨197K⟩Conforms to reference spectrum
    Assay (HPLC)USP ⟨621⟩, C18, 220 nm≥98.0 % (anhydrous basis)
    Melting rangeUSP ⟨741⟩188–192 °C
    Loss on dryingUSP ⟨731⟩, 105 °C, 2 h≤0.5 %
    Residue on ignitionUSP ⟨281⟩≤0.1 %
    Heavy metals (as Pb)USP ⟨231⟩ Method II≤20 ppm
    PalladiumICP‑MS, USP ⟨730⟩≤10 ppm
    Residual solventsGC‑HS, USP ⟨467⟩Per ICH Q3C: acetone ≤500 ppm, MTBE ≤500 ppm, ethyl acetate ≤500 ppm, heptane ≤500 ppm

    All incoming batches are released against this specification after sampling according to ANSI/ASQ Z1.4‑2008 level S‑3. During scale‑up from 1‑kg to 50‑kg scale, a duplicate analysis scheme that cross‑references HPLC with quantitative 1H NMR (ERETIC method) reduced outlier rejection events by 60 %, primarily by catching particulate contamination that selectively suppressed UV response. Long‑term stability data at 25 °C/60 % RH (ICH Q1A) covering 36 months show no purity drift beyond 0.3 % when the packaging seal integrity is maintained; any breach results in moisture ingress and the appearance of the hydrolysis product 2‑aminothiazole‑5‑carboxylic acid above the 0.5 % identification threshold within 45 days.